Lilly Mounjaro Zepbound highlights the worst entry points in pharma approvals and their proven impact on the market.
Pharma revenue growth is projected at 11-13% as exports expand beyond the US.
Compass psychedelic drug launch is paving the way for new treatments in mental health.